Selected published studies | Factors | Percentage | Locoregional control | Disease-free survival | Overall survival | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(%) | 2-year | 3-year | 5-year | 2-year | 3-year | 5-year | 2-year | 3-year | 5-year | |||
University of Texas M. D. Anderson Cancer Center, USA [6] | POTT | <11 wks | 64.2% | 81% | 78% | 76% | 64% | 58% | 48% | |||
>13 wks | 10% | 38% | 38% | 38% | 25% | 25% | 25% | |||||
IBOR | ≤6 wks | 54.7% | 78% | 78% | 75% | 68% | 58% | 48% | ||||
>6 wks | 45.3% | 58% | 50% | 48% | 50% | 32% | 25% | |||||
VU University Medical Center, Netherlands [7] | POTT | <11 wks | 12% | 86% | ||||||||
>13 wks | 45% | 71% | ||||||||||
OTTRT | ≤7 wks | 31% | 90-82% | 85-75% | 78-58% | 72-49% | 82-65% | 74-55% | ||||
>8 wks | 16% | 56% | 51% | 42% | 38% | 53% | 50% | |||||
University of Florida, USA [20] | POTT | ≤101 days | 63% | 70% | 70% | 70% | ||||||
>101 days | 17% | 50% | 40% | 30% | ||||||||
IBOR | ≤51 days | 57% | 72% | 72% | 72% | |||||||
>51 days | 17% | 56% | 50% | 40% | ||||||||
University of Florida College of Medicine, USA [22] | POTT | <100 days | 60% | |||||||||
>100 days | 14% | |||||||||||
University of Texas M. D. Anderson Cancer Center, USA [2] | IBOR | ≤6 wks | 77% | |||||||||
>6 wks | 64% | |||||||||||
University Hospital, Avda, Spain [21] | POTT | ≤150 days | 77% | |||||||||
>150 days | 63% | |||||||||||
IBOR | ≤ 50 days | 83% | ||||||||||
>50days | 68% | |||||||||||
OTTRT | ≤ 60 days | 75% | ||||||||||
>60 days | 68% | |||||||||||
FEMH, Taiwan | POTT | ≤11 wks | 42.1% | 92% | 84% | 94% | ||||||
>13 wks | 21.1% | |||||||||||
IBOR | ≤6 wks | 84.2% | ||||||||||
>6 wks | 15.8% | |||||||||||
OTTRT | ≤ 7 wks | 78.9% | ||||||||||
> 8 wks | 5.2% |